Maze Therapeutics, Inc., a biopharmaceutical company focused on developing precision medicines for renal, metabolic, and cardiovascular diseases, announced that CEO Jason Coloma, Ph.D., will present a ...
Monday - Friday, 2:00 - 3:00 PM ET In this article Maze Therapeutics has had a great run since its initial public offering in January — and CEO Jason Coloma is hoping that momentum continues as the ...
MAZEGalaspia C. Maze (nee Flannery) age 89 formerly of Harvey, Illinois passed away peacefully on August 6, 2010 at Arden Courts of South Holland. Preceded in death by her husband Matthew and son ...
Maze Therapeutics, Inc. (NASDAQ:MAZE) on Thursday shared clinical results from the Phase 1 healthy volunteer study of MZE782, an oral small molecule targeting the solute transporter, SLC6A19. MZE782 ...
Maze Therapeutics leverages its Compass platform to translate human genetic insights into de-risked, high-probability drug candidates. MZE829 targets APOL1-mediated kidney disease with a dual ...
An experimental Maze Therapeutics drug increased urinary excretion of compounds that are biological indicators of metabolic disease, early clinical trial results that suggest the molecule has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results